Drugs / seletalisib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02207595 | Aug 2014 → Feb 2015 | — | UCB Celltech | Completed | No outcome recorded |
| Phase 1 | NCT02303509 | Aug 2013 → Feb 2014 | psoriasis | UCB Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02610543 | Oct 2015 → Sep 2017 | Sjogren syndrome | UCB Celltech | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | seletalisib | “A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.” PMID 32949140 ↗ Mar 2021 |
| Known as | UCB5857 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02207595 ↗ |
| Action | Inhibit | “seletalisib, a potent and selective PI3Kδ inhibitor” PMID 32949140 ↗ Mar 20211“PI3-kinase p110-delta subunit inhibitor” CHEMBL4297648 ↗ |
| Modality | Small molecule | — CHEMBL4297648 ↗ |
| Route | Oral | “Route of Administration: Oral Use” NCT02207595 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4297648 ↗ |